

May 14, 2007



## **Kane Biotech Awarded Patent for Compositions and Methods to Inhibit Biofilm Formation**

WINNIPEG, MANITOBA -- (MARKET WIRE) -- 05/14/07 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, has been awarded Patent No. 2,452,032 to protect compositions and methods of inhibiting biofilm formation in a variety of applications, including medical devices. The patent, entitled "Synergistic Antimicrobial Compositions and Methods of Inhibiting Biofilm Formation", has been awarded by the Canadian Intellectual Property Office.

This is the second new patent awarded to Kane within the last six months, bringing the Company's estate of issued and pending patents to over thirty. The novel technology was developed by Kane's Research and Development team.

"We are very pleased to see our novel research recognized by patent offices at home and abroad. I believe this is a testament to our strong team and our research capabilities. We are extremely enthusiastic about the future of Kane as we continue to grow our patent estate and work to see our novel products commercialized", stated Mr. Gord Froehlich, President of Kane Biotech Inc.

An estimated 80% of all human bacterial infections involve biofilms. Biofilms pose human health problems as they develop on surfaces such as catheters, prosthetic implants, inner ears, teeth, gums, lungs and the urogenital tract. Biofilms also pose major problems in industry as they grow on surfaces of water tanks, pipes, and food processing containers and are difficult and costly to remove.

### **About Kane Biotech Inc.**

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability

to prevent and/or destroy biofilms in several medical and industrial applications.

#### Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading "Risk Factors" contained in Kane's final long-form prospectus dated March 12, 2007. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts:

Kane Biotech Inc.  
Gord Froehlich  
President  
(204) 477-7592  
(204) 453-1314 (FAX)  
Email: [gfroehlich@kanebiotech.com](mailto:gfroehlich@kanebiotech.com)  
Website: [www.kanebiotech.com](http://www.kanebiotech.com)